Logo

Caris Life Sciences CODEai

Oct 14, 2020

Caris Life Sciences has launched CODEai (Comprehensive Oncology Data Explorer), a real-world clinico-genomic data platform that uses artificial intelligence technology to integrate the company's catalog of molecular data with cancer treatment information and clinical outcomes data for more than 215,000 patients covering more than 1 million data points per patient.

Integrating genomically profiled patient cases with associated treatments and outcomes, CODEai allows for customized cohort analysis based on a variety of search queries including molecular profiling results, demographic data, diagnostic data, and treatment and survival data. The system also provides data visualization and advanced predictive analytics. The platform is available to members of the Caris Precision Oncology Alliance, a growing collaborative network of cancer centers, as well as to biopharma companies through collaborative relationships. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.